Global Patent Index - EP 3989976 A4

EP 3989976 A4 20230719 - LEMBOREXANT FOR TREATING SLEEP ISSUES

Title (en)

LEMBOREXANT FOR TREATING SLEEP ISSUES

Title (de)

LEMBOREXANT ZUR BEHANDLUNG VON SCHLAFSTÖRUNGEN

Title (fr)

LEMBOREXANT POUR LE TRAITEMENT DE PROBLÈMES DE SOMMEIL

Publication

EP 3989976 A4 20230719 (EN)

Application

EP 20832928 A 20200625

Priority

  • US 2019039333 W 20190626
  • US 2019006795 W 20191220
  • US 2020039674 W 20200625

IPC 8 full level

A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 25/20 (2006.01); A61P 25/28 (2006.01)

CPC (source: EP IL)

A61K 31/506 (2013.01 - EP IL); A61P 25/20 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 43/00 (2017.12 - EP IL)

Citation (search report)

  • [XY] MARGARETMOLINE ET AL: "EFFICACY AND TOLERABILITY OF LEMBOREXANT IN FEMALE AND MALE SUBJECTS WITH INSOMNIA EFFECT OF LEMBOREXANT ON SLEEP ARCHITECTURE IN OLDER ADULTS WITH INSOMNIA DISORDER", SLEEP, 1 January 1201 (1201-01-01), pages a150 - a151, XP093053299
  • [XY] MURPHY PATRICIA ET AL: "Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study", JOURNAL OF CLINICAL SLEEP MEDICINE, vol. 13, no. 11, 15 November 2017 (2017-11-15), US, pages 1289 - 1299, XP055778847, ISSN: 1550-9389, DOI: 10.5664/jcsm.6800
  • See references of WO 2020264201A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

EP 3989976 A1 20220504; EP 3989976 A4 20230719

DOCDB simple family (application)

EP 20832928 A 20200625